Partnership of New Brunswick Community-Based AIDS Organizations
A Harm Reduction Approach for Injection Drug Users (IDUs) Adopted February 2005
Issue Summary
Injection drug use is a serious health and social issue in Canada. The economic costs associated with injection drug use are substantial and rising, due, in part, to the spread of HIV and Hepatitis-C infections. A federal/provincial/territorial report in 2001 (Reducing the Harm Associated with Injection Drug Use in Canada) notes that 63% of new Hepatitis-C cases and over one third of new HIV cases are related to injection drug use. This study predicts that the direct and indirect costs of HIV/AIDS and Hepatitis-C attributable to injection drug use will be $8.7 billion over the next six years, if trends continue.
To read/download the entire Position Statement (.pdf) click on one of the links below.
Position Statement - English Position Statement - French Position
Hepatitis B
What is Hepatitis B?
Hepatitis B is a disease caused by a virus that attacks the liver. It is100 times easier to be infected with Hepatitis B as compared to HIV. About 90% of adults clear the virus from their system after infection. Click the link for the complete Info Sheet on Hepatitis B (.PDF)
Hepatitis B Info Sheet
LYMPHOMAGRANULOMA VENEREUM OR LGV
What is LGV?
LGV is a sexually transmitted infection caused by special types of chlamydia. It is caused by a bacteria as is regular chlamydia, but LGV causes a much more serious illness. It has been previously found in tropical countries. Since 2004, some cases were reported in the US and in certain European countries. In 2005, it has been reported in Canada. To date, LGV in Canada and the US has appeared in men having sex with men (MSM). Click the link for the complete Info Sheet on LGV (.PDF)
LGV Info Sheet
